Invivyd IVVD 深 沪
等待开盘 04-01 09:30:00 美东时间
1.30
+0.110
+9.24%
华盛通- 最 高1.34
- 今 开1.23
- 成交量 406.42万股
- 最 低 1.23
- 昨 收 1.19
- 总市值 3.67亿
- 52周最高 3.0699
- 市盈率 静 --
- 换手率 1.44%
- 52周最低 0.4613
- 委 比 -88.03%
- 总股本 2.83亿
- 历史最高 78.82
- 量 比 1.54
- 振 幅 9.24%
- 历史最低 0.3546
- 每 手 1
- 风险率 0.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Invivyd Announces Presentation at the World Vaccine Congress Washington
Invivyd’s Chief Scientific Officer, Robert Allen, Ph.D., presented at the World Vaccine Congress Washington on developing monoclonal antibody (mAb) therapies to address rapidly evolving viral threats. His presentation highlighted the potential of mAbs to tackle virus variation and improve treatment and prevention options for vulnerable populations. The World Vaccine Congress, a leading global vaccine event, emphasizes collaboration and innovation...
03-30 20:05
Invivyd FY revenue rises; operating expenses cut sharply
Invivyd FY revenue rises; operating expenses cut sharply Overview Biopharmaceutical company reported Q4 PEMGARDA net product revenue up 25% yr/yr Loss per share for 2025 beat analyst expectations Net loss for 2025 beat analyst estimates Outlook Invivyd expects top-line data from DECLARATION trial mi
03-05 20:17
Invivyd Q4 Earnings Assessment
Invivyd (NASDAQ:IVVD) announced its Q4 earnings on Thursday, March 5, 2026 at 0...
03-05 20:10
Invivyd Q4 EPS $0.02 Beats $(0.08) Estimate, Sales $17.207M Beat $15.525M Estimate
Invivyd (NASDAQ:IVVD) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.08) by 124.1 percent. This is a 113.33 percent increase over losses of $(0.15) per share from the same
03-05 20:06
BRIEF-Invivyd FY EPS USD -0.3 Vs. IBES Estimate USD -0.39
BRIEF-Invivyd FY EPS USD -0.3 Vs. IBES Estimate USD -0.39 Mar 05 (Reuters) - Invivyd FY revenue USD 53.426 million. FY net income USD -52.489 million vs. IBES estimate USD -57.8 million
03-05 20:03
Invivyd Names Michael Mina Chief Medical Officer
Invivyd Names Michael Mina Chief Medical Officer Invivyd Inc. appointed Michael Mina, M.D., Ph.D. as its Chief Medical Officer. Mina previously served as an assistant professor at the Harvard T.H. Chan School of Public Health, Harvard Medical School, and Brigham and Women’s Hospital, and has held ch
03-05 20:03
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
Invivyd reported Q4 2025 financial results, including $17.2M net product revenue for PEMGARDA, a 25% YoY increase, and $226.7M cash after 2025 capital raises. The company also announced the initiation of the VYD2311 Phase 3 trial and appointed Michael Mina, MD, as Chief Medical Officer. The DECLARATION trial achieved full enrollment and received FDA Fast Track designation. Research and development expenses decreased by 73%, while selling, general...
03-05 12:03
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
Invivyd公司宣布Michael Mina博士担任首席医学官，进一步强化其医疗领导团队。Mina博士拥有哈佛大学流行病学、免疫学和传染病领域的深厚背景，专注于COVID-19、麻疹等疾病研究，并在科学传播方面具有卓越能力。其加入将助力公司开发独家单克隆抗体，用于预防和治疗多种病毒威胁。
03-05 12:01
Invivyd Has Received and is Aligned With Advice From the FDA On LIBERTY Phase 3 Trial for VYD2311, the Company's Investigational Monoclonal Antibody to Prevent Covid-19, Versus Commercially Available mRNA COVID Vaccines
LIBERTY is part of the Company's broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable
02-03 20:13
